Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

AIMS: Navoximod (GDC‐0919, NLG‐919) is a small molecule inhibitor of indoleamine‐2,3‐dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolute bioavailability (aBA), determine the mass...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Ma, Shuguang, Suchomel, Julia, Yanez, Evelyn, Yost, Edward, Liang, Xiaorong, Zhu, Rui, Le, Hoa, Siebers, Nicholas, Joas, Lori, Morley, Roland, Royer‐Joo, Stephanie, Pirzkall, Andrea, Salphati, Laurent, Ware, Joseph A., Morrissey, Kari M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6624388/
https://ncbi.nlm.nih.gov/pubmed/30973970
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13961
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados